Testing personalized medicine: Patient and physician expectations of next-generation genomic sequencing in late-stage cancer care

European Journal of Human Genetics

Volumn 22, Issue 3, 2014, Pages 391-395

  Miller, Fiona A ^a,b   Hayeems, Robin Z ^a   Bytautas, Jessica P ^a   Bedard, Philippe L ^c   Ernst, Scott ^d   Hirte, Hal ^e   Hotte, Sebastien ^e   Oza, Amit ^c   Razak, Albiruni ^c   Welch, Stephen ^d   Winquist, Eric ^d   Dancey, Janet ^f   Siu, Lillian L ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e JURAVINSKI CANCER CENTRE   (Canada)

^f ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

cancer care; clinical sequencing; clinical trials; genetic testing; personalized medicine; qualitative research

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; DECISION MAKING; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PATIENT EDUCATION AS TOPIC; PATIENTS; PHYSICIANS; SELF REPORT; SEQUENCE ANALYSIS, DNA;

EID: 84894358831     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.158     Document Type: Article

References (44)

1. Hamburg M, Collins F: The path to personalized medicine. N Engl J Med 2010; 363: 301-304.
2. Chan I, Ginsburg G: Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet 2011; 12: 217-244.
3. Borden E, Raghavan D: Personalizing medicine for cancer: the next decade. Nat Rev Drug Discov 2010; 9: 343-344.
4. Schlisky R: Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010; 9: 363-366.
5. Roychowdhury S, Iyer M, Robinson D et al: Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3: 111ra21.
6. Wideroff L, Phillips K, Randahawa G et al: A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics 2009; 12: 233-244.
7. Kwon S, Cho H, Choi J, Jee B, Jo Y, Woo H: Perspectives of integrative cancer genomics in next generation sequencing era. Genomics Inform 2012; 10: 69-73.
8. Facio F, Brooks S, Loewenstein J, Green S, Biesecker L, Biesecker B: Motivators for participation in a whole-genome sequencing study: implications for translational genomics research. Eur J Hum Genet 2011; 19: 1213-1217.
9. Kohane E, Hsing M, Kong S: Taxonomizing, sizing and overcoming the incidentalome. Genet Med 2012; 14: 399-404.
10. Ku C-S, Wu M, Cooper D et al: Technological advances in DNA sequence enrichment and sequencing for germline genetic diagnosis. Expert Rev Mol Diagn 2012; 12: 159-173.
11. Green RC, Berg JS, Grody WW et al: ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15: 565-574.
12. van El C, Cornel M, Borry P et al: Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics. Eur J Hum Genet 2013; 21: 580-584.
13. Matsuyama R, Reddy S, Smith T: Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 2006; 24: 3490-3496.
14. McClement S, Chochinov H: Hope in advanced cancer patients. Eur J Cancer 2008; 44: 1169-1174.
15. Sulmasy D, Astrow A, He M et al: The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer 2010; 116: 3702-3711.
16. Wootten A, Abbott J, Siddons H, Rosenthal M, Costello A: A qualitative assessment of the experience of participating in a cancer-related clinical trial. Support Care Cancer 2011; 19: 49-55.
17. Pelligrini I, Rapti M, Extra J-M et al: Tailored chemotherapy based on tumour gene expression analysis: breast cancer patients' misinterpretaitons and positive attitudes. Eur J Cancer Care 2012; 21: 242-250.
18. Bueno-de-Mesquita J, van Harten W, Retel V et al: Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective communitybased feasibility study (RASTER). Lancet Oncol 2007; 8: 1079-1087.
19. Oratz R, Paul D, Cohn A, Sedlacek S: Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 2007; 3: 182-287.
20. Lo S, Mumby P, Norton J et al: Prospective multicenter study of the impact of the 21-Gene Recurrence Score Assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010; 28: 1671-1676.
21. Bonter K, Desjardins C, Currier N, Pun J, Ashbury F: Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open 2011; 1: e000110.
22. O'Neill S, Brewer N, Lillie S et al: Women's interest in gene expression analysis for breast cancer recurrence risk. J Clin Oncol 2007; 25: 4628-4634.
23. Andrykowski M, Burris J, Walsh E, Small B, Jacobsen P: Attitudes toward information about genetic risk for cognitive impairment after cancer chemotherapy: Breast cancer survivors compared with healthy controls. J Clin Oncol 2010; 28: 3442-3447.
24. McClellan K, Avard D, Simard J, Knoppers B: Personalized medicine and access to health care: potential for inequitable access? Eur J Hum Genet 2013; 21: 143-147.
25. Facio F, Eidem H, Fisher T et al: Intentions to receive individual results from whole-genome sequencing among participants in the ClinSeq study. Eur J Hum Genet 2013; 21: 261-265.
26. Issa A, Tufail W, Hutchinson J, Tenorio J, Poonam Baliga M: Assessing patient readiness for the clinical adoption of personalized medicine. Public Health Genomics 2009; 12: 163-169.
27. Gordon E, Griffin G, Wawak L, Pang H, Gollust S, Bernhardt B: "It's not like judgment day": public understanding of and reactions to personalized genomic risk information. J Genet Couns 2012; 21: 432-432.
28. Schwartz M, Peshkin B, Hughes C, Main D, Isaacs C, Lerman C: Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002; 20: 514-520.
29. Lerman C, Narod S, Schulman K et al: BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study. JAMA 1996; 275: 1885-1892.
30. Croyle R, Smith K, Botkin J, Baty B, Nash J: Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychol 1997; 16: 63-72.
31. Broadstock M, Michie S, Marteau T: Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet 2000; 8: 731-738.
32. Hallowell N: Doing the right thing: genetic risk and responsibility. Sociol Health Illn 1999; 21: 597-621.
33. Hallowell N, Foster C, Eeles R, Ardern-Jones A, Murday V, Watson M: Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information. J Med Ethics 2003; 29: 74-83.
34. Hallowell N, Ardern-Jones A, Eeles R et al: Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their family. Sociol Health Illn 2006; 28: 969-988.
35. Etchegary H, Miller F, de Laat S, Wilson B, Carroll J, Cappelli M: Decision-making about inherited cancer risk: exploring dimensinos of genetic responsibility. J Genet Couns 2009; 18: 252-264.
36. Metcalfe K, Poll A, Royer R et al: Screening for founder mutations in BRCA1 and BRCA2 in unselected jewish women. J Clin Oncol 2010; 28: 387-391.
37. Tran B, Brown A, Bedard P et al: Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. Int J Cancer Supp 2013; 132: 1547-1555.
38. Sandelowski M: What's in a name? Qualitative description revisited. Res Nurs Health 2010; 33: 77-84.
39. Thorne S: Interpretive description. Walnut Creek, CA, USA: Left Coast Press, 2008.
40. Charmaz K: Constructivist and objectivist grounded theory; In: Denzin N, Lincoln Y editors. The SAGE handbook of qualitative research. Thousand Oaks, CA, USA: Sage, 2000.
41. Charmaz K: Constructing grounded theory: a practical guide through qualitative analysis. London, UK: Sage, 2006.
42. Hallowell N, Cooke S, Crawford G, Lucassen A, Parker M: Distinguishing research from clinical care in cancer genetics: theoretical justifications and practical strategies. Soc Sci Med 2009; 68: 2010-2017.
43. Forrest K, Simpson S, Wilson B et al: To tell or not to tell: Barriers and facilitators in family communication about genetic risk. Clin Genet 2003; 64: 317-326.
44. Wilson B, Etchegary H.: Family communication of genomic information; In: Teryack K editor. Handbook of genomics and the family: Psychosocial context for children and adolescents. New York, NY, USA: Springer, 2010.